Lupus & antiphospholipid syndrome
Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment
Authors' conclusion
Our study has implicated the substantial heterogeneity and disease-specific immune cell subsets in belimumab-treated and non-belimumab-treated SLE patients.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with/without belimumab treatment and normal controls; Peripheral blood mononuclear cells (PBMCs)24.869 PBMCs analysed
- Comparison
- SLE patients with vs without belimumab treatment, and SLE vs normal controls
- Outcome
- Peripheral immune cell landscape
Methodological detailssingle-cell RNA sequencing, flow cytometry
- Single-cell RNA sequencing
- Flow cytometry
Main finding
As reported in the abstract
- SLE vs normal controls (NC): significant upregulation of CD3+T, CD8+T, CD3+PD-1+T and CD8+PD-1+T cells
- SLE vs NC: CD16+CD56+NK cell, CD14+CD206+ monocyte and CD14+CD163+ monocyte proportions and CD3+CD4+T/CD3+CD8+T ratio significantly reduced
- After belimumab: CD19+B and CD3+PD-1+T cell proportions significantly decreased in peripheral blood
- 11 cell clusters identified by single-cell RNA sequencing
Original publication
Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment. Clin Exp Rheumatol. Published 3 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →